You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Immunotherapeutic advances in gastric cancer
|
|---|---|
| Published in |
Surgery Today, February 2021
|
| DOI | 10.1007/s00595-021-02236-2 |
| Pubmed ID | |
| Authors |
Akira Yoneda, Tamotsu Kuroki, Susumu Eguchi |
| Abstract |
Advanced gastric cancers are responsible for overwhelming human suffering and death. Despite the development of combination chemotherapies, the survival rates of patients with gastric cancer remain unsatisfactory. Given the growing evidence of the benefits of immunotherapy as an alternative treatment for other cancers such as advanced melanoma, non-small cell lung cancer, renal cell carcinoma, and refractory Hodgkin's lymphoma, researchers have begun to explore its application in the treatment of gastric cancer. Three types of immunotherapy have shown promising effects against gastric cancer: immune checkpoint inhibitors, chimeric antigen rector (CAR)-T cells, and tumor vaccines. Clinical trials have used either immuno-oncology monotherapies or combination immuno-chemotherapies to improve the overall survival times and objective response rates of patients with gastric cancer. We review the clinical efficacy of immunotherapy including checkpoint inhibitors, CAR‑T, and tumor vaccines, in the treatment of gastric cancer. Based on initial evidence, we believe that immunotherapy could positively impact the natural history and improve the outcomes of a subgroup of patients with gastric cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 17% |
| Student > Doctoral Student | 3 | 13% |
| Other | 2 | 9% |
| Student > Master | 2 | 9% |
| Student > Ph. D. Student | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 8 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 39% |
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Immunology and Microbiology | 2 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Materials Science | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 8 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2021.
All research outputs
#20,687,221
of 23,283,373 outputs
Outputs from Surgery Today
#675
of 1,000 outputs
Outputs of similar age
#470,558
of 548,444 outputs
Outputs of similar age from Surgery Today
#14
of 23 outputs
Altmetric has tracked 23,283,373 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,000 research outputs from this source. They receive a mean Attention Score of 2.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 548,444 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.